TGFB1 and cancer: In this context, single-molecule treatment targeting TGF-β induced PD-L1 in its downstream without effecting the non-canonical arm of the signaling pathway may have the potential for an optimal suppression of cancer progression, a benefit not provided by combining independent therapies.